Amid Paxlovid scarcity, Korea looks for alternatives
Social affairsMar 25, 2022
South Korea is looking to bring in alternative therapies amid a shortage of Paxlovid, the COVID-19 antiviral pill from Pfizer. The only antibody drug on the market here, Celltrion’s Regkirona, was suspended from use a month ago after evidence emerged that it was ineffective against omicron. Being distributed from Saturday is Merck’s antiviral pill Lagebrio, whose approval here was delayed until...